A day after suspending its study of the use of ketamine on agitated people by paramedics, Hennepin Healthcare said it would halt similar clinical trials that seek consent from patients only after treatment.
Dr. William Heegaard, chief medical officer for the hospital system, appeared before the Hennepin County Board Tuesday to respond to ethical concerns over a ketamine study in which patients are enrolled without their consent.
Heegaard defended Hennepin Healthcare's practices as complying with rules and regulations, but said the hospital wants to pause its research and address complaints from the public.
"The community is hurting. I see it," Heegaard said. "We don't want to add to the pain and distrust. … We can do more."
Heegaard did not say the number of studies that will be halted, but said it would be every one with a similar consent policy, called a "waiver of consent," unless stopping the study would put patients at risk.
After County Commissioner Peter McLaughlin and state Sen. Jeff Hayden, DFL-Minneapolis, released a statement denouncing the study as "unconscionable and unethical," the hospital announced Monday it would suspend the ketamine study.
Hennepin Healthcare's decision to halt clinical studies is the latest response to concern and outrage over the findings of a city of Minneapolis draft report into the use of ketamine during EMS calls. The city of Minneapolis has hired former Acting U.S. Attorney General Sally Yates to investigate whether its police officers improperly influenced paramedics' decision to use the drug.
Heegaard's appearance before commissioners comes two days after a Star Tribune story describing how the draft report questioned whether the hospital's study played a role in some people being injected with ketamine.